|View printer-friendly version|
|August 24, 2004 5:15 p.m.|
|FTC CLEARS TEVA/ACTIVE BIOTECH AGREEMENT|
Jerusalem, Israel and Lund, Sweden, August 24, 2004 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and Active Biotech AB (Stockholm: ACTI.ST) announced today that the companies' previously announced June 14th agreement to develop and commercialize laquinimod, Active Biotech's novel immunomodulatory compound, which has the potential to be an orally available disease modifying treatment of multiple sclerosis (MS), has been cleared by the United States Federal Trade Commission under Hart-Scott-Rodino Act procedures. With this consent, cooperation between Teva and Active Biotech comes into immediate effect.